Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (13)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. UNR/CSDE1 expression is critical to maintain invasive phenotype of colorectal cancer through regulation of c-MYC and epithelial-to-mesenchymal transition

    Journal of Clinical Medicine, Vol. 8, Núm. 4

2017

  1. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer

    Oncotarget, Vol. 8, Núm. 25, pp. 40169-40180

2016

  1. C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer

    Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790

2015

  1. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer

    Clinical Cancer Research, Vol. 21, Núm. 2, pp. 347-356

  2. Pyrosequencing-based assays for rapid detection of HER2 and HER3 mutations in clinical samples uncover an E332E mutation affecting HER3 in retroperitoneal leiomyosarcoma

    International Journal of Molecular Sciences, Vol. 16, Núm. 8, pp. 19447-19457

2014

  1. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

    British Journal of Cancer, Vol. 110, Núm. 11, pp. 2700-2707

  2. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1842, Núm. 9, pp. 1823-1829

  3. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential

    Molecular Cancer Therapeutics, Vol. 13, Núm. 4, pp. 938-947

  4. Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer

    British Journal of Cancer, Vol. 111, Núm. 4, pp. 756-762

  5. Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells

    Journal of Cancer Research and Clinical Oncology

  6. Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer

    International Journal of Colorectal Disease